<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01421095</url>
  </required_header>
  <id_info>
    <org_study_id>ORT study</org_study_id>
    <nct_id>NCT01421095</nct_id>
  </id_info>
  <brief_title>Ovarian Reserve Testing in Female Young Adult Cancer Survivors</brief_title>
  <official_title>Ovarian Reserve Testing in Female Young Adult Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Young adult cancer survivors constitute an under served population to whom fertility&#xD;
      potential is particularly important. For female young adult patients, cancer treatment such&#xD;
      as alkylating chemotherapy are toxic to the finite number of eggs they have, resulting in&#xD;
      risks of infertility and premature menopause related to ovarian failure. Reproductive issues&#xD;
      are a major concern for young cancer survivors, but one that is understudied. Young cancer&#xD;
      survivors have few tools to measure post-treatment ovarian reserve, or the quantity and&#xD;
      quality of remaining eggs4. Accurate determination of ovarian reserve and fertility potential&#xD;
      would not only be an important research tool, but also directly impact clinical management.&#xD;
      The purpose of this study is to test if basal and provocative ovarian reserve testing can&#xD;
      predict return of menses in female young adult cancer survivors, to compare basal and&#xD;
      provocative ovarian reserve testing results between female young adult cancer survivors and&#xD;
      healthy controls, and to compare basal and provocative ovarian reserve testing results&#xD;
      between female young adult cancer survivors on and off of combined estrogen and progesterone&#xD;
      hormone products.&#xD;
&#xD;
      Participants will be asked to keep track of their periods over three months. If a participant&#xD;
      is taking birth control pills, patches, or vaginal ring, they will asked to come off the&#xD;
      birth control for 3 months. Participants will also be asked to undergo ovarian reserve&#xD;
      testing by blood draws and pelvic ultrasounds at the start and end of the 3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Same as brief summary&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 1, 2011</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Return of menses</measure>
    <time_frame>3 months</time_frame>
    <description>Self reported via bleeding calenders</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood levels of FSH</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of estradiol</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of AMH</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood levels of inhibin B</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Cancer</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Basal Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant FSH</intervention_name>
    <description>Each participant will recieve recombinant FSH (150 IU) intravenously</description>
    <arm_group_label>Basal Testing</arm_group_label>
    <other_name>Gonal F</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenarchal&#xD;
&#xD;
          -  Cancer diagnosis&#xD;
&#xD;
          -  Prior exposure to gonadotoxic therapy, inclusive of chemothearpy, pelvic or total body&#xD;
             irradiation, unilateral oophorectomy&#xD;
&#xD;
          -  A minimum of 1 year since completion of gonoadotoxic therapy&#xD;
&#xD;
          -  Intact uterus&#xD;
&#xD;
          -  At least one ovary&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Estrogen receptor positive cancers&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. Irene Su, MD MSCE</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>91351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 15, 2011</study_first_submitted>
  <study_first_submitted_qc>August 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2011</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Hui-Chun Irene Su</investigator_full_name>
    <investigator_title>Assistant Professor of Reproductive Medicine</investigator_title>
  </responsible_party>
  <keyword>Fertility</keyword>
  <keyword>adolescent</keyword>
  <keyword>young adult</keyword>
  <keyword>cancer survivors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

